Exchange: NASDAQ·Updated 04:10 PM EST
LGVN logo

LGVN Longeveron Inc - Ordinary Shares - Class A

$1.66
$0.16
(8.79%)
Today
Closed $1.66
$0.00
(0.00%)
After Hours
Reported EarningsNov 12
Mkt Cap$6.14M
Vol26,057.00

About LGVN

Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffer on October 9, 2014 and is headquartered in Miami, FL.
48

Neutral Sentiment

How do you feel about LGVN?

skyrockets_Inc
$LGVN AI analysis of merger valuation. I've done this same chart on all of my previous investements and it's been very accurate each time. Looks like $2/share is a likely floor w/ additional upside for any value received for Laromestrocel
1
4
skyrockets_Inc
$LGVN LOL. No one was ever buying this company. This company is buying a private biotech instead. It's called a reverse merger or 'business combination'. My guess is news on this comes in the next 3-4 weeks MAX
6
Naser111111
$LGVN 🚀 | Positive Results, Renewed Optimism! The latest ELPIS II results have renewed hope for the company’s heart treatment, showing a statistically significant reduction in major adverse cardiovascular events (P=0.043), despite the earlier failure to meet the primary endpoint. I believe these findings could trigger a stock rebound and a potential revaluation, especially with the upcoming American Heart Association presentation on November 8 and anticipated FDA discussions. I remain optimistic about LGVN’s future. My confidence is rooted in its scientific achievements, not daily stock price fluctuations. 🚀
1
3
skyrockets_Inc
$LGVN Added more on the drop, officially at 250k shares at 1.75/share avg. News likely in next 4 weeks imo.
5
yanlucas
$LGVN There could be an explosive move here if some excellent news regarding the pipeline comes out. The market cap is 5 million—it could potentially reach 300 million—and the float is only 3 million. In short, that would mean over $100 per share. It could perform even better than DRUG; I’m not saying it’s a certainty, but the conditions are there.
3
Naser111111
$LGVN | Positive Development in Share Ownership. Recent filings indicate increased holdings by certain investors, including a significant reported position of 250,000 shares, representing approximately 7.7% of Class A common stock. This development follows the sharp decline in the stock price during October, suggesting renewed investor interest worth monitoring, although the exact timing of the share purchases remains unconfirmed. This reflects my personal opinion and does not constitute investment advice.
2
Naser111111
$LGVN | Positive Signs Offer Reassurance to Investors. Longeveron’s Q3 results showed reduced losses and continued efforts to preserve cash. The company remains focused on developing promising therapies for Alzheimer’s disease, age-related frailty, and heart conditions, while exploring strategic partnerships and potential mergers through Lucid Capital Markets. Despite financial challenges, LGVN still holds valuable therapeutic assets and strategic opportunities that could open new paths for growth. There are reasons for optimism, but future outcomes are not guaranteed. This reflects my personal opinion and does not constitute investment advice.
1
BarryJets
THE BEST TRADER ON STOCKTWITS FOR REAL FOLLOW on Stocktwits! <- He called you OMH for 2900%, insane this guy is on FIRE. Recent runners $LGVN $ADXN and $AEHL
1
Stock_Catcher
$LGVN Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
1
Rayvio_News_Filter
$LGVN 🤝 Longeveron Inc. initiated a strategic review and retained Lucid Capital Markets as financial advisor to explore strategic opportunities, including a potential business combination, to maximize stockholder value. Curated for market relevance
StocktwitsEarnings
$LGVN Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$1.91 up 51.40% YoY • Reported revenue of $0.12M down -14.29% YoY • Longeveron expects September 30, 2026 cash and cash equivalents, based on current operating plans and cash conservation measures, to fund operations into the first quarter of 2027.
GrumpySumurai
$LGVN pumping today on 10x normal volume after the ELPIS II heart trial data at AHA. Primary endpoint missed but the MACE secondary hit, and they're exploring a sale or merger. Last 4 of its 6 pumps were followed by an offering or reverse split though.
Rayvio_News_Filter
$LGVN 🤝 Longeveron Inc. retained Lucid Capital Markets, LLC as financial advisor to explore strategic opportunities, including a potential business combination. Curated for market relevance
Rayvio_News_Filter
$LGVN 🏥 Longeveron Inc. announced updated results from its Phase 2b ELPIS II trial of laromestrocel as an adjunct to Stage 2 palliative surgery in 40 infants with hypoplastic left heart syndrome, following additional analysis; the trial previously did not meet the primary RVEF endpoint. Actionable market event
NoneNone00
$LGVN mgmt last cc said they had enough events for statistical significance if their assumptions were correct - i highly doubt they were counting on stat significance with 9 events - which makes this pr appear to be insincere at best - no explanation on how mace events went from 31 to 9
sniky25
$LGVN really good News today: ELPIS II 2 Data in HLHS Selected for Late-Breaking Science Program Podium Presentation in the American Heart Association’s (AHA) 2026 Scientific Sessions

Advertisement|Remove ads.